Canada Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2022-2027)

The Canada Anti-Rheumatic Drug Market was valued at US$0.73 billion in 2020 and is projected to reach US$0.84 billion by 2027. This growth represents a Compound Annual Growth Rate (CAGR) of 2.18% over the forecast period, indicating a steady expansion driven by various market factors.

The market's growth is primarily driven by Canada's ageing population, with seniors outnumbering youth, as the prevalence of chronic back pain and arthritis is higher in this demographic. Additionally, continuous new drug approvals from Health Canada, such as AbbVie's RINVOQ®, and the availability of over-the-counter (OTC) drugs further boost market expansion.

The Canadian Antirheumatic Drugs market is segmented by type of disease (osteoarthritis, rheumatoid arthritis, gout, lupus, others), type of molecule (pharmaceuticals, biopharmaceuticals), and sales channel (prescription, OTC). The rheumatoid arthritis sector is predicted to hold a significant market share due to its rising prevalence, linked to factors like unhealthy lifestyles, metabolic diseases, age, and obesity.

By sales channel, the prescription-based drug segment currently holds the biggest market share, attributed to the rise in specialist hospitals for medical conditions. However, the over-the-counter (OTC) medicine sector is anticipated to grow at the quickest rate during the forecast period, driven by increased awareness of rheumatoid arthritis treatment options.

New drug approvals from Health Canada, exemplified by AbbVie's RINVOQ® for moderate to severe active rheumatoid arthritis, are a key factor in market players capturing larger shares. These approvals introduce innovative treatments, enhancing the therapeutic landscape and indicating a continuous effort by biopharmaceutical companies to meet evolving patient needs and expand market presence.

Beyond demographic shifts and new drug approvals, the market is expected to benefit from improvements in biosimilar and innovative biologics. These advancements are anticipated to open up new business prospects within the sector, providing enhanced treatment options and driving market evolution during the forecast period.